Lucid Diagnostics
LUCD
35 hedge funds and large institutions have $17.8M invested in Lucid Diagnostics in 2021 Q4 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
8.99% more ownership
Funds ownership: 0% → 8.99% (+9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LM
Luminus Management
Houston,
Texas
|
+$10.2M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.53M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.02M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$1.96M |
| 5 |
CC
Covalis Capital
London,
United Kingdom
|
+$1.09M |
Top Sellers
LUCD Hedge Fund Activity: Q4 2021 in Review
35 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Lucid Diagnostics (LUCD) for Q4 2021, worth a combined $17.8M.
Buyers outnumbered sellers: 35 funds opened new LUCD positions and 0 closed out — a net gain of 35 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Luminus Management, opening a new position worth an estimated $10.2M.
- 35 institutional investors held Lucid Diagnostics (LUCD) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $17.8M of Lucid Diagnostics stock for Q4 2021.
- 35 funds opened new Lucid Diagnostics positions in Q4 2021 and 0 closed out, a net change of +35 holders.
- The largest Lucid Diagnostics buyer in Q4 2021 was Luminus Management, an estimated $10.2M added.
Based on aggregated 13F filings for Q4 2021.